

**INDIA**  
**PERIPHERAL ARTERY DISEASE AND CRITICAL LIMB ISCHEMIA**

Mary L. Yost  
404-520-6652  
THE SAGE GROUP

THE SAGE GROUP, LLC  
RESEARCH AND CONSULTING  
23 Ridge Rd  
Beaufort SC 29907

Copyright Pending  
January 18, 2018

All rights reserved, including the right of reproduction  
in whole or in part in any form.

## **REFERENCES (FIRST AND LAST PAGES)**

1. Yost ML. India Peripheral arterial disease, thromboangiitis obliterans & critical limb ischemia epidemiology and markets. Atlanta (GA) THE SAGE GROUP; 2009.
2. Yost ML. Critical limb ischemia Volume I. United States epidemiology 2016 supplement. Beaufort (SC): THE SAGE GROUP; 2016.
3. Yost ML. Western Europe prevalence and incidence of peripheral artery disease and critical limb ischemia. Beaufort (SC): THE SAGE GROUP; 2017.
4. Yost ML. South America: diabetes, peripheral artery disease and critical limb ischemia. Atlanta (GA): THE SAGE GROUP; 2013.
5. Yost ML. Mexico: diabetes, peripheral artery disease and critical limb ischemia. Atlanta (GA): THE SAGE GROUP; 2014.
6. Yost ML. Japan peripheral artery disease and critical limb ischemia prevalence and incidence. Beaufort (SC): THE SAGE GROUP; 2017.
7. Yost ML. China peripheral artery disease and critical limb ischemia prevalence and incidence. Beaufort (SC): THE SAGE GROUP; 2017.
8. Yost ML. Critical limb ischemia Volume I. United States epidemiology. Atlanta (GA): THE SAGE GROUP; 2010.
9. Yost ML. Critical limb ischemia Volume II. Western Europe epidemiology. Atlanta (GA): THE SAGE GROUP; 2010.
10. International Diabetes Federation (IDF). IDF Diabetes Atlas 2015. 7th edition. [Internet. Accessed 2017, Jul.] Available at: [http://www.oedg.at/pdf/1606\\_IDF\\_Atlas\\_2015\\_UK.pdf](http://www.oedg.at/pdf/1606_IDF_Atlas_2015_UK.pdf).
11. Ueshima H, Sekikawa A, Miura K, et al. Cardiovascular disease and risk factors in Asia: a selected review. Circulation 2008; 118(25):2702-2709.
12. Ma RC, Chan JC. Type 2 diabetes in East Asians: similarities and differences with populations in Europe and the United States. Ann N Y Acad Sci 2013, Apr; 1281: 64-91.
13. Mohan V, Pradeepa R, Anajna RM. Diabetes in India-an epidemiological review. Current controversies and consensus in diabetes management. 1st edn. 2015:1. [Internet. Accessed 2017, Dec.] Available at: [http://mdrfeprints.in/897/1/Diabetes\\_in\\_India\\_An\\_epidemiological\\_review.pdf](http://mdrfeprints.in/897/1/Diabetes_in_India_An_epidemiological_review.pdf).
14. Shrivastava U, Misra A, Mohan V, et al. Obesity, diabetes and cardiovascular diseases in India: public health challenges. Curr Diabetes Rev. 2017;13(1):65-80.
15. Kindo BK, Himanshu R, Parmar K, et al. Socioeconomic and demographic trends in the prevalence of type 2 diabetes in India. J Soc Health Diabetes 2016;4:90-101.

82. Wang Y, Li J, Xu YW, et al. [Prevalence of peripheral arterial disease and correlative risk factors among natural population in China]. Abstract. Zhonghua Xin Xue Guan Bing Za Zhi. 2009, Dec;37(12):1127-31. Chinese.
83. Norgren L, Hiatt WR, Dormandy JA, et al; TASC II Working Group. Inter-Society Consensus for the Management of Peripheral Arterial Disease (TASC II). *J Vasc Surg* 2007, Jan; 45 Suppl S: S5-67.
84. McDermott MM. Lower extremity manifestations of peripheral artery disease: the pathophysiologic and functional implications of leg ischemia. *Circulation Research* 2015; 116(9): 1540-1550.
85. Diehm C, Allenberg JR, Pittrow D, et al. Mortality and vascular morbidity in older adults with asymptomatic versus symptomatic peripheral artery disease. *Circulation* 2009;120: 2053-61.
86. Mahoney EM, Wang K, Keo HH, et al. Vascular hospitalization rates and costs in patients with peripheral artery disease in the United States. *Circ Cardiovasc Qual Outcomes* 2010; 3:642-51.
87. Yost ML. The real cost of peripheral artery disease. Atlanta (GA): THE SAGE GROUP; 2011.
88. Hasimu B, Li J, Yu J, et al. Evaluation of medical treatment for peripheral arterial disease in Chinese high-risk patients. *Circ J* 2007, Jan;71(1):95-9.
89. Yamazaki T, Goto S, Shigematsu H, et al; REACH Registry Investigators. Prevalence, awareness and treatment of cardiovascular risk factors in patients at high risk of atherothrombosis in Japan. *Circ J* 2007, Jul; 71(7):995-1003.
90. Conte MS, Bandyk DF, Clowes AW, et al. Risk factors, medical therapies and perioperative events in limb salvage surgery: observations from the PREVENT III multicenter trial. *J Vasc Surg* 2005; 42(3): 456-65.
91. Armstrong EJ, Chen DC, Westin GG, et al. Adherence to guideline-recommended therapy is associated with decreased major adverse cardiovascular events and major adverse limb events among patients with peripheral arterial disease. *J Am Heart Assoc* 2014, Apr 10;3(2): e000697.
92. Subherwal S, Patel MR, Kober L, et al. Missed opportunities: despite improvement in use of cardioprotective medications among patients with lower-extremity peripheral artery disease, underuse remains. *Circulation*. 2012, Sep 11;126(11):1345-54.
93. Aiman U, Haseen MA, Beg MH, et al. Profile of atherosclerotic risk factors and management in patients of peripheral arterial disease at a tertiary care teaching hospital of North India. *Indian Journal of Pharmaceutical Sciences*. 2014;76(6):504-509.

## **CONTACT INFORMATION**

### Research

Mary L. Yost  
President and Senior Analyst  
Telephone (404) 520-6652  
[yost@thesagegroup.us](mailto:yost@thesagegroup.us)

### Marketing

Harrington Witherspoon  
Senior Vice President  
Marketing  
Telephone (404) 816-0746  
[witherspoon@thesagegroup.us](mailto:witherspoon@thesagegroup.us)